[
  {
    "ts": null,
    "headline": "Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program",
    "summary": "NORTHAMPTON, MA / ACCESS Newswire / April 15, 2025 / As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered ...",
    "url": "https://finnhub.io/api/news?id=edd1d10bdb4700dfb29349854caf6d113648f933e72169846115c8da7c165240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744721400,
      "headline": "Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program",
      "id": 133922245,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "NORTHAMPTON, MA / ACCESS Newswire / April 15, 2025 / As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered ...",
      "url": "https://finnhub.io/api/news?id=edd1d10bdb4700dfb29349854caf6d113648f933e72169846115c8da7c165240"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons GILD is Risky and 1 Stock to Buy Instead",
    "summary": "In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=65bfa7ddccee67b02bf1df7acf859493f97c40bfff78c6d6d0b497be4c077c2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744707943,
      "headline": "3 Reasons GILD is Risky and 1 Stock to Buy Instead",
      "id": 133922246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "In a sliding market, Gilead Sciences has defied the odds, trading up to $106.42 per share. Its 24% gain since October 2024 has outpaced the S&P 500’s 6.9% drop. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=65bfa7ddccee67b02bf1df7acf859493f97c40bfff78c6d6d0b497be4c077c2c"
    }
  }
]